TRC Cap­i­tal's mi­ni-ten­der of­fer ir­ri­tates a flus­tered Bio­gen

6 years ago
Pharma

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will ...

6 years ago
R&D
Pharma

Some of the best con­nect­ed play­ers in the San Diego hub or­ga­nize launch round for an­oth­er biotech with an eye on ...

6 years ago
Startups
R&D

As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

6 years ago
Financing
Startups

Long-term in­clisir­an da­ta sug­gest The Med­i­cines Com­pa­ny/Al­ny­lam drug will flour­ish in piv­otal study, dis­rupt 'bad' ...

6 years ago
R&D

$1.3B Keytru­da wind­fall will be used to ac­cel­er­ate trans­la­tion­al drug R&D in the UK

6 years ago
Startups
R&D

Dana-Far­ber’s 4-year le­gal bat­tle shines a light on the ori­gins of PD-1 re­search — forc­ing a reck­on­ing on who ...

6 years ago
People
R&D

Take­da re­ceives ad­di­tion­al FDA ap­proval for GI drug; Can­cer Re­search UK to test gem­c­itabine for ad­vanced pan­cre­at­ic ...

6 years ago
News Briefing

Un­der fire for Tru­va­da US pric­ing at House hear­ing, Gilead chief O'­Day touts R&D costs, as­serts gov­ern­ments patents ...

6 years ago
Pharma

EMA im­pos­es for­mal lim­it on Xel­janz pre­scrip­tion as reg­u­la­tors con­tin­ue to re­view safe­ty con­cerns

6 years ago
Pharma

Bio­gen ex­ec Paul McKen­zie heads to CSL as COO; Pul­ma­trix CEO re­signs

6 years ago
Peer Review

Ab­b­Vie con­cedes an­oth­er PhI­II can­cer drug flop as glioblas­toma de­feats lat­est as­sault

6 years ago
R&D

Fol­low­ing its lat­est set­back, Achillion posts some en­cour­ag­ing PoC da­ta for lead drug

6 years ago
R&D
Pharma

Take­da, Fra­zier cre­ate Phath­om Phar­ma­ceu­ti­cals to spur de­vel­op­ment of GI drug vono­prazan in $140M play

6 years ago
Pharma

Bet­ter than CAR-T? Al­ready prep­ping for a US launch, Mor­phoSys posts stel­lar DL­B­CL da­ta to field against No­var­tis, ...

6 years ago
R&D

All in on nov­el tar­get GSK-3β, Ac­tu­ate Ther­a­peu­tics rais­es $21M+ to bankroll am­bi­tious PhI/II

6 years ago
Financing

Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

6 years ago
Pharma

Ab­b­Vie/Roche's Ven­clex­ta wins fourth ap­proval; WuXi, fel­low CRO Al­ta­sciences ink deal

6 years ago
News Briefing

Can a lit­tle known drug in As­traZeneca's pipeline make a come­back as a PARP add-on? Yale sci­en­tists ex­plain how

6 years ago
Discovery

Af­ter a long march with Cabo, Ex­elix­is is ex­pand­ing its fo­cus with an an­ti­body-drug con­ju­gate deal

6 years ago
R&D
Pharma

Genen­tech lines up a new au­toim­mune R&D al­liance on a 'po­ten­tial­ly trans­for­ma­tive' tech

6 years ago
R&D
Discovery

An­a­lysts spot­light the win­ners — and losers — on AS­CO pre­view night

6 years ago
R&D
Pharma

As Dai­ichi Sankyo-part­nered breast can­cer drug march­es to­ward fin­ish line, As­traZeneca brings in Cana­di­an sci­en­tist ...

6 years ago
People

Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

6 years ago
R&D
First page Previous page 933934935936937938939 Next page Last page
A service from the Financial Times